Taiwan
· Delayed Price · Currency is TWD Medeon Biodesign Statistics
Total Valuation
Medeon Biodesign has a market cap or net worth of TWD 3.94 billion. The enterprise value is 2.53 billion.
| Market Cap | 3.94B |
| Enterprise Value | 2.53B |
Important Dates
The next estimated earnings date is Friday, November 1, 2024.
| Earnings Date | Nov 1, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Medeon Biodesign has 92.14 million shares outstanding. The number of shares has increased by 0.06% in one year.
| Shares Outstanding | 92.14M |
| Shares Change (YoY) | +0.06% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 11.34% |
| Owned by Institutions (%) | 3.53% |
| Float | 47.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 18.60 |
| PB Ratio | 2.05 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.12 |
| EV / Sales | 11.93 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.89 |
Financial Position
The company has a current ratio of 9.21, with a Debt / Equity ratio of 9.89.
| Current Ratio | 9.21 |
| Quick Ratio | 8.99 |
| Debt / Equity | 9.89 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.22 |
| Interest Coverage | -143.76 |
Financial Efficiency
Return on equity (ROE) is -36.75% and return on invested capital (ROIC) is -21.43%.
| Return on Equity (ROE) | -36.75% |
| Return on Assets (ROA) | -20.01% |
| Return on Capital (ROIC) | -21.43% |
| Revenue Per Employee | 5.43M |
| Profits Per Employee | -20.79M |
| Employee Count | 39 |
| Asset Turnover | 0.08 |
| Inventory Turnover | 13.54 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.18% in the last 52 weeks. The beta is 0.71, so Medeon Biodesign's price volatility has been lower than the market average.
| Beta (5Y) | 0.71 |
| 52-Week Price Change | -10.18% |
| 50-Day Moving Average | 45.28 |
| 200-Day Moving Average | 44.94 |
| Relative Strength Index (RSI) | 39.82 |
| Average Volume (20 Days) | 33,363 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Medeon Biodesign had revenue of TWD 211.86 million and -810.63 million in losses. Loss per share was -8.81.
| Revenue | 211.86M |
| Gross Profit | 18.08M |
| Operating Income | -883.43M |
| Pretax Income | -864.11M |
| Net Income | -810.63M |
| EBITDA | -840.48M |
| EBIT | -883.43M |
| Loss Per Share | -8.81 |
Balance Sheet
The company has 1.64 billion in cash and 193.60 million in debt, giving a net cash position of 1.45 billion or 15.71 per share.
| Cash & Cash Equivalents | 1.64B |
| Total Debt | 193.60M |
| Net Cash | 1.45B |
| Net Cash Per Share | 15.71 |
| Equity (Book Value) | 1.96B |
| Book Value Per Share | 20.90 |
| Working Capital | 1.54B |
Cash Flow
In the last 12 months, operating cash flow was -816.16 million and capital expenditures -57.94 million, giving a free cash flow of -874.11 million.
| Operating Cash Flow | -816.16M |
| Capital Expenditures | -57.94M |
| Free Cash Flow | -874.11M |
| FCF Per Share | -9.49 |
Margins
| Gross Margin | 8.53% |
| Operating Margin | -416.98% |
| Pretax Margin | -407.86% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -412.58% |
Dividends & Yields
Medeon Biodesign does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.06% |
| Shareholder Yield | -0.06% |
| Earnings Yield | -20.58% |
| FCF Yield | -22.16% |
Stock Splits
The last stock split was on August 23, 2023. It was a forward split with a ratio of 1.049992864.
| Last Split Date | Aug 23, 2023 |
| Split Type | Forward |
| Split Ratio | 1.049992864 |